Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-1RL2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL1RL2 ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View IL1RL2 Products |
| Gene Delivery | IL1RL2 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View IL1RL2 Products |
| Benchmark Ab | Anti-IL1RL2 (Spesolimab Biosimilar Sequence). Recombinant positive control for ligand-blocking assays. | View IL1RL2 Products |
| Validator | IL1RL2 siRNA Set. For knockdown verification and specificity controls. | View IL1RL2 Products |
| Co-Receptor | IL1RAP (IL-1RAcP). Required signaling co-receptor; essential for heterodimerization assays. | View IL1RAP Products |
| Natural Antagonist | IL36RN (IL-36Ra). Endogenous receptor antagonist for competitive binding studies. | View IL36RN Products |
| Selectivity Panel | IL1R1 (IL-1R1). Counter-screening for IL-1 family specificity. | View IL1R1 Products |
| Off-Target Panel | IL1RL1 (ST2). IL-1 receptor subfamily homolog for strict counter-screening. | View IL1RL1 Products |
| Agonist Ligand (IL-36α) | IL-36α protein for ligand competition assays. | View IL36A Products |
| Agonist Ligand (IL-36β) | IL-36β protein for ligand competition assays. | View IL36B Products |
| Agonist Ligand (IL-36γ) | IL-36γ protein for ligand competition assays. | View IL36G Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human / Cyno / Mouse IL1RL2 ortholog ECD-Fc proteins available with >95% purity; Sequence identity verified by Mass Spec. |
| IL-1 Family Selectivity Screening | Homolog panel proteins (IL-1R1, IL-33R/ST2, IL-1R2) strictly verified by SPR/BLI for off-target assessment. |
| Heterodimeric Co-Receptor Dependency | IL-1RAcP complex formation assays supported by high-avidity ECD-Fc formats; IL-36α/β/γ ligand competition available. |
| Lack of Clinical Controls | Clinical Benchmark Antibodies (Spesolimab biosimilar sequence) included for assay standardization. |
| False Positives / Specificity | Validated siRNA included for receptor knockdown specificity verification. |
Live IL-1RL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Alternative Search Term (IL-36R)
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The IL-1RL2 (IL-36R) therapeutic landscape has entered a new phase with the first regulatory approvals. Boehringer Ingelheim's Spesolimab (anti-IL-36R) secured FDA approval in 2022 for Generalized Pustular Psoriasis (GPP) flares, validating the target's clinical utility in neutrophil-driven inflammation. The competitive environment is rapidly evolving from first-generation blocking antibodies toward next-generation modalities including oral small molecules (DICE Therapeutics, Ventus Therapeutics) and bispecific constructs targeting synergistic pathways.
Current R&D focus is expanding beyond the orphan indication of GPP into broader autoimmune markets: plaque psoriasis, ulcerative colitis, hidradenitis suppurativa, and atopic dermatitis. As the first wave of therapeutics reaches Phase III for these larger indications, differentiation will depend on subcutaneous formulation stability, tissue penetration in epithelial barriers, and the ability to avoid broad IL-1 pathway immunosuppression through precise epitope selection. Additionally, next-wave efforts are exploring high-concentration subcutaneous formulations and Fc-engineered variants that extend dosing intervals without compromising receptor blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking mAb (IV) | Boehringer Ingelheim (Spesolimab), AnaptysBio (Imsidolimab) | GPP, Palmoplantar Pustulosis | Competitive Binding Assay (vs. IL-36α/β/γ); Requires high-purity ECD-Fc with native conformation |
| Blocking mAb (Sub-Q) | Boehringer Ingelheim, AnaptysBio | Hidradenitis Suppurativa, IBD, Plaque Psoriasis | High-Concentration Stability & Viscosity Testing (Need aggregate-free antigen standards) |
| Small Molecule Antagonist | DICE Therapeutics, Ventus Therapeutics | IBD, Psoriasis | Heterodimer Disruption Assay (IL-1RL2/IL-1RAcP); Need full-length Lentivirus cell lines |
| Bispecific | Preclinical/Undisclosed | Autoimmune (Combination) | Dual-binding validation; Cross-reactivity panel against IL-1 family |
| ADC (Emerging) | Exploratory | Neutrophilic Dermatoses | Internalization Assay via Lentivirus-stable cell lines |